Phase 1RecruitingPriority 3 · Moderate priorityNCT06733441
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Plain-language summary
This Phase 1 trial is comparing TLN-254 and TLN-254 against other options for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. Patients are randomly assigned to different treatment groups to see which approach works best. It is available at 4 US locations.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
TLN-254 (DRUG): TLN-254 will be administered orally at a specified dose on specified days depending on treatment allocation. | TLN-254 (DRUG): TLN-254 will be administered orally at a specified dose on specified days.
- Drugs / treatments
- TLN-254, TLN-254
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details